X

Trial Profile

A phase II study of TAS102 for advanced/recurrent esophageal cancer resistant/intolerable to 5-FU, Platinum compounds, and Taxane

Status: Completed

Phase of Trial: Phase II

Latest Information Update: 11 May 2018

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Tipiracil/trifluridine (Primary)
Indications Oesophageal cancer
Focus Therapeutic Use
Acronyms ECTAS

Most Recent Events

12 Sep 2017 Primary endpoint (Progression-free survival rate at 3 months) has not been met as per the results presented at the 42nd European Society for Medical Oncology Congress
12 Sep 2017 Results presented at the 42nd European Society for Medical Oncology Congress
21 Jun 2017 Status changed from active, no longer recruiting to completed.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com